Adlai Nortye (ANL) Accumulated Expenses (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Accumulated Expenses of $3.1 million for Q4 2025, up 2.64% year-over-year from $3.1 million in Q4 2024, and down 35.56% quarter-over-quarter from $4.9 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Accumulated Expenses (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Accumulated Expenses for 4 consecutive years, with $3.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses rose 2.64% year-over-year to $3.1 million; the TTM figure through Dec 2025 stood at $3.1 million (up 2.64% YoY), while the FY2025 annual figure was $3.1 million, up 2.64% from the prior year.
- Accumulated Expenses slipped to $3.1 million in Q4 2025 per ANL's latest filing, from $4.9 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $4.9 million in Q2 2025 and bottomed at $3.1 million in Q4 2024.
- Historically, Accumulated Expenses has averaged $3.7 million across 4 years, with a median of $3.7 million in 2022.
- Annual changes were most pronounced in 2024 — Accumulated Expenses declined 19.69% — and 2025, when it gained 28.73%.
- Adlai Nortye's Accumulated Expenses stood at $3.6 million in 2022, then increased by 5.3% to $3.8 million in 2023, then retreated by 19.69% to $3.1 million in 2024, then increased by 2.64% to $3.1 million in 2025.
- Business Quant data shows ANL's Accumulated Expenses at $3.1 million in Q4 2025, $4.9 million in Q2 2025, and $3.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.22 Mn |
| Dec 31, 2025 | 3.74 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Dec 31, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.79 Mn |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2022 | 3.88 Mn |